Myeloproliferative neoplasms (MPN; myeloproliferative disorders) are clonal stem cell diseases, defined by excessive production of cells in one or more hematopoietic lineages. Primary myelofibrosis (PMF), polycythemia vera (PV), essential thrombocythemia (ET), as well as chronic myelogenous leukemia are included in the current 2008 WHO classification for MPNs. 1 In 2005, a missense mutation in the JAK2 tyrosine kinase (JAK2V617F) leading to constitutive activation of JAK2, was found in about 95% of PV patients, 40% of ET patients and 40% of PMF patients. 2 This provided insights into common lesions leading to pathogenesis of PV, ET and PMF.
To investigate other possible lesions present in MPNs, we performed microarray analysis on 26 granulocyte samples from PMF (4), ET (5), PV (6) and normal (11) individuals (Table 1) . We also determined the JAK2 mutational status of these samples using an adaptation of the method described by Baxter et al. Figure 1S) . A total of 246 genes were found to be dysregulated between normal and MPN granulocytes, including those associated with TGFb and TNFa signaling pathways, and cell cycle (Supplementary Table 1S ).
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Expression levels of several of these genes were confirmed by quantitative real-time (qRT)-PCR ( Figure 1) . Particularly, overexpression of the TGFb-regulated transcription factors, RUNX3 and TIEG1, are clearly seen in MPN compared to normal granulocytes ( Figure 1a ). Several studies have recently shown that elevated levels of TGFb can promote myelofibrosis. 3 TGFb is produced and secreted predominantly by megakaryocytes, platelets and monocytes, and it stimulates collagen synthesis. 3 Several other genes that may play a role in development of fibrosis in MPN are also dysregulated. For example, metalloproteinase (ADAM8), integrins (ITGA2B and ITGB3) and antimetastasis-associated genes (NME2). ITGA2B and ITGB3 by microarray analysis were much more highly expressed in PMF than in either ET or PV; and in turn, these genes were greatly overexpressed in ET and PV compared to normal samples. qRT-PCR confirmed higher expression of ITGA2B in ET and PV samples while PMF and normal samples had similar levels of expression of this gene (Figure 1b ). ITGB3 was also overexpressed in MPNs compared to normal samples, but the levels of overexpression was not statistically significant ( Figure 1b) . The disintegrin gene, ADAM8, was significantly downregulated in PMF granulocytes compared to PV, ET and normal samples.
TNFa-associated genes, such as TNFAIP3 and CIAS1, were overexpressed in all types of MPNs compared to normal, suggesting a disrupted inflammatory response in MPN (Figure 1b) . Dysregulation of cell cycle regulatory genes, such as PER1 and CCNL2, in MPN samples were also found. This is perhaps not surprising as this study compared granulocytes that are derived from the abnormal 'MPN/proliferative' clone to normal granulocytes. Interestingly, PER1 was highly overexpressed in ET samples compared to normal samples, and only mildly overexpressed in PV cases.
A second objective of this study was to identify genes that would allow us to discriminate between the different diseases, and from normal individuals ( Table 2 ). As described above, expression of PER1 could distinguish ET from the other MPNs. Other examples include glycoprotein GP1BB and erythrocyte membrane protein EPB42 genes that are clearly overexpressed in PMF compared to PV and ET, which in turn, had much higher expression compared to the normal samples. Also, PRV1 was overexpressed in PV samples compared to ET or PMF. Our data demonstrate that MPN samples can be stratified into specific diseases based upon the level of expression of several genes.
Amongst the dysregulated genes, RUNX3 has a precedent in tumor biology; it and its family members are transcription factors associated with cell proliferation and differentiation.
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RUNX1 (AML1) is frequently involved in chromosomal translocations resulting in oncogenic fusion proteins including t(8;21)(q22;q22) (AML1/ETO) in FAB M2 acute myelogenous leukemia (AML), one of the most frequent karyotypic abnormalities in AML. RUNX2 is required for osteoblast differentiation and bone development, and heterozygous loss-of-function of RUNX2 produces the bone disease cleidocranial dysplasia. Expression of RUNX3 parallels the expression pattern of RUNX1 in the hematopoietic system, but in contrast to RUNX1, no inactivating mutations of RUNX3 have been found in AML blasts. 5 However, high expression of RUNX3, together with FLT3 mutations in childhood AML, has been associated with unfavorable outcome. Low levels of RUNX3, on the other hand, have been found in low-risk AML with inv(16). 6 Immunohistochemical staining for RUNX3 protein was performed on bone marrow aspirates of 7 ET, 10 PMF, 1 PV and 10 normal samples. Two of 10 normal samples (no. 295 and no. 79) revealed weak staining in some cells ( Figure 2 ). The remaining nine normal samples were clearly negative. All PMF samples were negative due to staining being especially difficult because of predominantly fibrotic tissue and hypocellular bone marrow, as can be seen in PMF no. 534. The single PV sample was also negative for RUNX3 (data not shown). Three of seven ET samples stained strongly for RUNX3 (two of these are presented in Figure 2 : no. 383 and no. 860). In fact, all three ET samples showed very prominent nuclear staining of RUNX3, consistent with its role as a transcription factor. Analysis of RUNX3 mRNA expression in AML cell lines revealed that RUNX3 levels were highest in the erythroleukemia (AML M6) cell line HEL (Figure 2b ). The second highest cell line was KG-1 and these cells were established from a patient who had erythroleukemia. The mean relative RUNX3 mRNA expression of all the myeloid cell lines (640 ± 315) is comparable to the mean level of RUNX3 mRNA expression in the MPN granulocytes (693 ± 302). Normal granulocytes show significantly lower expression of RUNX3 than either MPN granulocytes or myeloid leukemia cells.
Since RUNX3 expression was elevated in MPN granulocytes and AML cells, we were interested to find out what happens to RUNX3 during myeloid differentiation. We chose HL-60 cells as our model for granulocytic and monocytic differentiation. Figure 2c ). In addition, induction of differentiation towards neutrophils with 1.5% (v/v) dimethyl sulfoxide (DMSO) showed a slight delay in induction of RUNX3 expression; but nonetheless, upregulation of RUNX3 (8-9 fold) was observed at day 6, which rapidly returned to basal levels by day 7. Similarly, when treated with 0.5 mM 1,25-dihydroxyvitamin D3 to differentiate HL-60 cells towards monocytes, we observed a similar induction of RUNX3 expression at day 6 that returned to basal levels at day 7 (Figure 2c) . Similar experiments were performed in NB4 and U937 cells resulting in similar regulation of RUNX3 (data not shown). Our data suggest that RUNX3 may be initially involved in myeloid differentiation but returns to basal levels as the cells undergo terminal differentiation toward granulocytes or monocytes. It had been experimentally shown that overexpression of RUNX3 increased the proportion of mature CD8 thymocytes, pointing to the role of RUNX3 in differentiation of these cells also. Furthermore, neutrophils isolated from MPN patients are functionally impaired in their ability to fight infection compared to those from normal individuals. Thus, the high level of RUNX3 in MPN granulocytes might indicate that these cells are not completely and functionally mature granulocytes and are arrested at an earlier stage of maturation/differentiationFcomparable to day 5 ATRA-treated, or day 6 DMSO-treated/Vitamin D3-treated HL-60 cells.
Runx3, in mice, has also been shown to regulate TGFbmediated cell function in dendritic cells, as well as integrin expression in T cells. Thus, the role of RUNX3 in MPN appears to be associated with both TGFb signaling/myelofibrosis and leukocyte development. In other studies, Runx3 (murine homolog) knockout mice have hyperplasia of the epithelial cells of the glandular stomach. 7 Gastric epithelial cells were less sensitive to the growth-inhibitory effect of TGFb and apoptosis Letters to the Editor was suppressed in these cells compared to those in wild-type mice. Furthermore, inactivation of Runx3 by hemizygote deletion and DNA methylation of the promoter region was found in 90% of stage IV gastric cancers. These data suggest that Runx3 is a tumor suppressor gene in the TGFb signaling pathway. However, recently Salto-Tellez et al. 8 showed overexpression of RUNX3 protein in human basal cell carcinomas, which suggests that RUNX3 may have a dual role, as a tumor suppressor and as an oncogene.
Lastly, in light of the discovery of the JAK2 V617F mutation in MPN, we examined if this mutation had an impact on the genes expressed in MPNs. In total, 12 of 13 normal samples had wildtype JAK2 products only. The remaining sample (patient no. 45) had both wild-type and mutant bands; and later, we discovered that this individual did in fact have ET (personal communication).
Of the MPN samples, 5 had wild-type JAK2 products only, while 10 samples (including no. 45) had at least one JAK2 V617F allele (Table 1) . Re-analysis of our microarray data (where available), comparing MPNs with JAK2 V617F mutation to those that had only wild-type JAK2 and to normal samples revealed that approximately 100 genes were differentially expressed between the wild-type JAK2 and JAK2 V617F MPN groups. A subset of genes showing the highest levels of dysregulated expression is presented in Supplementary Table 2S . Despite reports suggesting that the JAK2 V617F mutation ultimately leads to the upregulation of JAK2 itself, we did not find JAK2 to be upregulated in our analysis. In addition, other genes associated with JAK2 activity, for example STAT3, SHP2 and SOCS3 were not increased in their expression in MPN samples with JAK2 V617F mutation compared to those without the abnormality. Abbreviations: ET, essential thrombocythemia; PMF, primary myelofibrosis; PV, polycythemia vera. A, genes differentiating PV from ET, PMF and normal. B, genes differentiating ET from PV, PMF and Normal. C, genes differentiating PMF from PV, ET and Normal. All mean gene expression levels in experimental samples have been compared to the mean level of expression in normal samples:mmm, 420-fold overexpression; mm, 10-to 20-fold overexpression; m, 2-to 9-fold overexpression; k, 2-to 5-fold downregulation; kk, 6-to 10-fold downregulation; kkk, 410-fold downregulation; 2, similar expression level to normal samples. Thus, changes in the level of phosphorylation of these target proteins are more likely to be important. In summary, we have identified several genes that may give us valuable insight into the pathophysiological abnormalities of myeloproliferative diseases and could provide potential markers that may be useful for diagnosis of these diseases. 
